PGR and neoplasm: In case of MBC, ECOG status, age, oestrogen receptor, HER2 and progesterone receptor (PR) status of the tumour, time to metastasis, number of metastatic sites, line of therapy, type of therapy and log-transformed CTCs and tdEVs were evaluated as potential risk factors.